Ratings DiaSorin S.p.A.

Equities

DIA

IT0003492391

Real-time Borsa Italiana Other stock markets 10:48:21 2024-04-18 am EDT			5-day change	1st Jan Change
89.68 ^EUR	-0.97%		+2.54%	-3.78%

04:14pm	Marshall Wace moves on Leonardo and OVS.	AN
10:14am	More buying on stock markets; MFE good after accounts	AN

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company's enterprise value to sales, at 4.61 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DIASORIN S.P.A.	-3.78%	5.14B		B
BIOMÉRIEUX	-1.39%	12.58B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-19.65%	6.82B		B-
AUTOBIO DIAGNOSTICS CO., LTD.	-7.82%	4.22B		C
LANTHEUS HOLDINGS, INC.	+3.97%	4.21B		C
10X GENOMICS, INC.	-49.25%	3.47B		D+
ANDON HEALTH CO., LTD.	+8.57%	2.65B	-	-
VITROLIFE AB	-13.15%	2.25B		B-
MYRIAD GENETICS, INC.	-1.88%	1.69B		C
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.	-12.09%	1.48B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes